Business
Takeda's FRUZAQLA™ (fruquintinib) publicly reimbursed in Quebec for the treatment of metastatic colorectal cancer (mCRC)
Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by Régie de l'assurance maladie (RAMQ) for people in Quebec, under certain criteria, as a treatment for adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates, for available standard therapies.1
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"text","content":"TORONTO, Aug. 28, 2025 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by Régie de l'assurance maladie (RAMQ) for people in Quebec, under certain criteria, as a treatment for adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates, for available standard therapies.1","length":433,"tagName":"p"},{"type":"image","alt":"Takeda Canada Inc. (CNW Group/Takeda Canada Inc.)","displaySize":"","headline":null,"caption":"Takeda Canada Inc. (CNW Group/Takeda Canada Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":210,"url":"https://media.zenfs.com/en/cnwgroup.com/29410b106cfc37218ed074d6535726ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5th6jTQ5KXt5spfDB2R4MQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM3MDtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/29410b106cfc37218ed074d6535726ff","width":400,"height":210}},"href":"https://mma.prnewswire.com/media/2759885/Takeda_Canada_Inc__Takeda_s_FRUZAQLA___fruquintinib__publicly_re.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"FRUZAQLA received market authorization by Health Canada in September 2024, followed by positive reimbursement recommendations by Canada's Drug Agency (CDA-AMC) and Institut national d'excellence en santé et services sociaux (INESSS).","length":241,"tagName":"p"},{"type":"text","content":""We are pleased to see Quebec reimbursing this new treatment to benefit people in the province living with this terminal cancer," said Filomena Servidio-Italiano, President & CEO, Colorectal Cancer Resource & Action Network. "The majority of deaths occur among those diagnosed with colorectal cancer in the metastatic setting. Having a treatment that supports people at the metastatic phase of the disease is crucial, for it can help these individuals achieve potential improved outcomes, including survival and quality of life."","length":557,"tagName":"p"},{"type":"text","content":"mCRC refers to cancer of the colon that has spread to other parts of the body (called distant metastasis), such as to the liver or lungs.2 In 2024, over 25,000 people were diagnosed with colorectal cancer (CRC) in Canada with over 9,000 dying...